Sanofi said the results are strong enough to support a new indication in the US and EU for Libtayo, a PD-1 inhibitor that is already FDA-approved in advanced cutaneous squamous cell carcinoma.

The study enrolled women with squamous cell carcinoma and adenocarcinoma forms of cervical cancer, and the death rate in those subgroups was reduced by 27% and 44%, respectively, with Libtayo.

SAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care ... in the U.S. The most common type of penile cancer is squamous cell penile cancer, accounting for 95% of cases.

Cemiplimab gained its first US approval in 2018 for use in locally advanced or metastatic cutaneous squamous cell carcinoma. Like other ICIs, and unlike HHIs, cemiplimab seeks to restimulate the ...

It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ...

post-FDA approval of Unloxcyt for metastatic cutaneous squamous cell carcinoma. Checkpoint faced financial struggles with only $4.7m cash and a net loss of $9.7m last quarter, making the ...

Ashfaq Marghoob provides skin cancer care to the residents of Long Island at MSK’s dedicated skin cancer center in Hauppaugue. Most cases of squamous cell carcinoma can be cured when found early and ...